Erratum to Lee et al. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. Neuro Oncol (2015) 17 (6): 862–867 first published online January 7, 2015 doi:10.1093/neuonc/nou350.
The statement concerning potential conflicts of interest was inadvertently omitted from this article. The following should have been stated:
David Schiff served in an advisory capacity for Genentech; Jeffrey Raizer served as an advisor and was paid a consulting fee by Genentech; Tracy Batchelor served as an advisor for Novartis and Genentech; Rameen Beroukhim was a paid consultant for Novartis; Patrick Wen was an advisor for Novartis and a paid consultant for Novartis and Genentech.